Posted by Michael Wonder on 30 Jan 2024
Regulatory applications accepted in the US and Japan for Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) in relapsed or refractory follicular lymphoma and relapsed or refractory mantle cell lymphoma
30 January 2024 - US FDA grants both follicular lymphoma and mantle cell lymphoma applications priority review.
Bristol Myers Squibb today announced three regulatory acceptances from the US FDA and Japan’s Ministry of Health, Labour and Welfare for Breyanzi (lisocabtagene maraleucel).
